Home › Dermatomyositis
Dermatomyositis clinical trials recruiting in the U.S.
26 studies for Dermatomyositis are recruiting participants at sites across the United States.
Cities with the most studies
- Durham, NC8 studies
- Washington, DC7 studies
- New York City, NY5 studies
- Pittsburgh, PA5 studies
- Houston, TX5 studies
- Boston, MA5 studies
- Baltimore, MD4 studies
- Philadelphia, PA4 studies
- Miami, FL4 studies
- Aurora, CO3 studies
- Kansas City, KS3 studies
- Jacksonville, FL3 studies
- Phoenix, AZ3 studies
- Cleveland, OH3 studies
- New Haven, CT3 studies
By state
- Arizona4 studies
- California9 studies
- Colorado4 studies
- Connecticut3 studies
- Florida7 studies
- Illinois3 studies
- Kansas4 studies
- Maryland9 studies
- Massachusetts5 studies
- New York6 studies
- North Carolina8 studies
- Ohio5 studies
- Pennsylvania7 studies
- Texas6 studies
Recently updated studies
FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)
RecruitingPhase 2
Ages 18 to 60 · All sexes · Updated Sep 29, 2026 · NCT07111065Environmental Risk Factors for the Anti-synthetase Syndrome
RecruitingObservational studyHealthy volunteers welcome
Ages 2 to 100 · All sexes · Updated Sep 28, 2026 · NCT01276470Natural History of Inflammatory Muscle Diseases
RecruitingObservational studyHealthy volunteers welcome
Ages 2 to 120 · All sexes · Updated Sep 24, 2026 · NCT05738824A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 24, 2026 · NCT06455449Adult and Juvenile Myositis
RecruitingObservational studyHealthy volunteers welcome
Ages 2 to 100 · All sexes · Updated Sep 24, 2026 · NCT00017914Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
RecruitingPhase 2/3
Ages 6 to 75 · All sexes · Updated Sep 17, 2026 · NCT06154252A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Sep 15, 2026 · NCT06916806A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT05895786A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
RecruitingPhase 1
Ages 18 to 74 · All sexes · Updated Sep 10, 2026 · NCT07085104FT839 in Autoimmune Diseases
RecruitingPhase 1/2
Ages 18 to 70 · All sexes · Updated Sep 2, 2026 · NCT07800871A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT06698796Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT07486869Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Jul 27, 2026 · NCT07089121Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
RecruitingPhase 1
Ages 18 to 85 · All sexes · Updated Jul 22, 2026 · NCT06371417A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 14, 2026 · NCT07115745Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 9, 2026 · NCT07138898Intralesional Injection of STS in Treatment of Calcinosis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 5, 2026 · NCT06672822Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Apr 27, 2026 · NCT07160205Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
RecruitingObservational study
Ages 18 and older · All sexes · Updated Mar 30, 2026 · NCT02945345Rheumatology Patient Registry and Biorepository
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 99 · All sexes · Updated Feb 13, 2026 · NCT04402086A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
RecruitingObservational study
Ages 18 and older · All sexes · Updated Feb 11, 2026 · NCT07403188MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)
RecruitingObservational study
Ages 7 and older · All sexes · Updated Jan 28, 2026 · NCT07374107Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis
RecruitingPhase 2
Ages 18 to 89 · All sexes · Updated Oct 8, 2025 · NCT06857240Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis
RecruitingPhase 1
Ages 25 to 72 · All sexes · Updated May 21, 2025 · NCT06298019From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.